The review paper, Regorafenib for the Treatment of Sarcoma, was recently published in Current Treatment Options in Oncology, 23 (11):1477-1502 (2022).

We are pleased to share a snapshot of the paper in this video from Prof. Robert Maki, along with accompanying slides and an infographic summary of the findings.

Physicians face challenges in selecting the most appropriate and effective treatments for sarcomas. In this paper, experts summarise the unmet needs of this patient group and review the current trial data to examine the safety profile and clinical activity of regorafenib in sarcoma subtypes.

 

Clinical takeaways:

  • Regorafenib demonstrated benefit in patients with osteosarcoma, Ewing sarcoma and non-adipocytic soft tissue sarcomas who had progressed on prior therapy
  • Patients who have otherwise limited treatment options may benefit from regorafenib therapy

Dr Maki is a medical oncologist who has focused for over 20 years to understand tumors arising from connective tissues, which include sarcomas and other aggressive tumors that do not metastasize, such as desmoid tumors. These tumors represent less than 1% of all cancers that happen in adults. I work with patients with these diagnoses to find the right treatment for the 70 or more types of bone and soft tissue sarcomas and other soft tissue tumors. As part of this work, I also reserach new medications for cancer in general, a field called developmental therapeutics. In my research, I seek to find new medications that may be useful for sarcoma patients, and try to figure out why they work or not. I work closely with colleagues at Penn Medicine, the Children's Hospital of Philadelphia, and with other national and international teams of researchers such as SARC, the Sarcoma Alliance for Research through Collaboration, to improve the understanding and treatment of sarcomas.

Prof. Robert Maki has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

 American Society for Clinical Oncology,  Bayer, Deciphera, Kayopharm, Peel Therapeutics and Tracon.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
SARCOMA CONNECT

SARCOMA CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Karyopharm Therapeutics.

Meet the experts Independent IME approved

Other programmes of interest

symposium Masterclass / Symposium
Oncology 
ER+/HER2- metastatic breast cancer: ESMO Breast Cancer 2026 Satellite Symposium highlights

Experts discuss 2nd line+ treatment strategies in endocrine therapy-eligible patients

Experts
Prof. Nadia Harbeck, Dr Tiffany Traina, Prof. Frederik Marmé
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jun 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs only.
conference-update Conference update
Oncology 
Highlights from ASCO 2026

Expert insights on the latest data

Experts
Dr Herbert Loong, Dr Isabel Preeshagul, Prof. Mark Socinski, Prof. Evan Yu, Prof. Hans Prenen, Dr Paolo Tarantino
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jun 2026
  • Non-accredited Independent Medical Education

Infographic / Flashcard
Oncology Rare diseases 
EP-NEC at a glance

Understanding EP-NEC, emerging treatments, and patient care strategies

Experts
Meredith Cummins
  • download Downloadable
    Resources
  • clock 1 MIN
  • calendar May 2026

This programme has been sponsored by Boehringer Ingelheim
eks
EKS / On-demand webinar
Oncology 
The evolving TROP2-directed ADC landscape in metastatic NSCLC

Strategies to optimise the treatment experience

Experts
Prof. Nicolas Girard, Dr Louise Lim, Dr Jacob Sands, Mrs Stephanie McDonald
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 58 MIN
  • calendar May 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
conference-update Conference update
Oncology 
Oncogene-addicted NSCLC highlights from ELCC 2026

Expert insights on the latest NSCLC data

Experts
Prof. Nicolas Girard
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
ISLB Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Video podcast
Oncology 
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Experts
Dr Carlos Barrios, Prof. Gary Tse, Oncology Brothers (Moderators)
Endorsed by
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Daiichi Sankyo